BB Biotech (BION)

Business description

BION is a Switzerland-domiciled investment company, targeting attractive long-term returns from predominantly mid-/large-cap biotech companies with established product portfolios (sales and earnings) and promising pipeline candidates. It is benchmarked against the NASDAQ Biotech Index, but is managed bottom-up with a concentrated 20-35 stock portfolio.

Stock data

Market cap.CHF3304.6m
Last closeCHF59.65
High / Low (52 weeks)CHF60.8 / CHF42.1
Stock market listingSW, IM
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamInvestment Companies
SectorInvestment Companies

Other companies in sector Show

Aberdeen New Dawn Investment Trust Aberdeen New Thai Investment Trust
Aberdeen Private Equity Fund Aberdeen UK Tracker Trust
AcenciA Debt Strategies Acorn Income Fund
Alliance Trust Altamir SCA
Amphion Innovations APQ Global
Aurelius Bailador Tech Investments
Bankers Investment Trust (The) Biotech Growth Trust (The)
BlackRock Greater Europe Investment Trust BlackRock Hedge Selector
BlackRock Latin American Inv. Trust British Portfolio Trust
Brunner Investment Trust (The) Canadian General Investments
Carador Income Fund Charles Stanley
Circle Property City Natural Resources
Conversus Capital CQS Rig Finance Fund
CVC Credit Partners Detour Gold
Deutsche Beteiligungs Dexion Commodities
Diverse Income Trust (The) DouglasBay Capital
Dunedin Enterprise Investment Trust DW Catalyst Fund
Edinburgh Worldwide Investment Trust (The) European Assets Trust
European Investment Trust Plc (The) F&C Managed Portfolio Growth
F&C Managed Portfolio Income F&C US Smaller Companies
Fidelity China Special Situations Fidelity European Values
Finsbury Growth & Income Trust Foreign & Colonial Investment Trust
Gartmore Growth Opportunities Gartmore Irish Growth Fund
Geiger Counter Limited GLI Alternative Finance
Global Resources Investment Trust Golden Prospect Precious Metals
Hansa Trust HarbourVest Global Private Equity
HarbourVest Senior Loans Europe HBM Healthcare Investments
Heliad Equity Partners Henderson Alternative Strategies Trust
Henderson Far East Income Henderson Global Trust
Henderson Global Trust Henderson International Income Trust
HSBC Infrastructure Company Infrastructure India
International Biotechnology Trust Invesco Asia Trust
Invesco Income Growth Trust Is Private Equity
JP Morgan Private Equity Limited JPMorgan Brazil Investment Trust
JPMorgan European Smaller Companies Trust JPMorgan Global Convertibles Income Fund
JPMorgan Global Growth & Income JPMorgan Indian Investment Trust
Jupiter Green Investment Trust Jupiter UK Growth Investment Trust
Jupiter US Smaller Companies JZ Capital Partners Limited
Lazard World Trust Fund Leaf Clean Energy Company
LMS Capital Lowland Investment Company
LPEQ Martin Currie Asia Unconstrained Trust
Martin Currie Global Portfolio Trust Middlefield Canadian Income
Miton Global Opportunities Miton Income Opportunities Trust
New City Energy Ocean Wilsons Holdings
Pacific Assets Trust Phaunos Timber Fund
Polar Capital Global Healthcare Trust PXP Vietnam Fund
Qatar Investment Fund Rathbone Brothers
RENN Universal Growth Investment Trust Schroder AsiaPacific Fund
Schroder Global Real Estate Securities ScotGems
Scottish Oriental Smaller Companies Securities Trust of Scotland
Seneca Global Income & Growth Trust Sigma Capital Group
Standard Life Equity Income Trust Standard Life Investments Property Income Trust
Standard Life Pvt. Equity Trust Standard Life UK Smaller Companies Trust
Strategic Equity Capital Taiwan Fund (The)
Templeton Emerging Markets Investment Trust Tetragon Financial Group
The Law Debenture Corporation The Merchants Trust
The North American Income Trust The Scottish Investment Trust
Tiso Blackstar Group TR European Growth trust
UK Commercial Property Trust Utilico Emerging Markets
Vietnam Holding Asset Management Vietnam Infrastructure Fund
VinaCapital Vietnam Opportunity Fund VinaLand
Vision Opportunity China Fund WAM Active
WAM Capital WAM Research
Witan Investment Trust Witan Pacific Investment Trust
Worldwide Healthcare Trust YFM Equity Partners

Company news

Biotech will continue to deliver 'double-digit growth' - Daniel Koller

Mon, 26 Jun 2017 16:52:30 GMT

A Chartists Perspective on BB BIOTECH AG – Ord-Shs (BBZA.DE)

Mon, 26 Jun 2017 18:11:15 GMT

Analysts See $0.36 EPS for TriMas (TRS); Bb Biotech Ag Has Decreased By $5.00 ...

Mon, 26 Jun 2017 15:00:00 GMT

Bb Biotech Ag Boosted Intra (ITCI) Stake by $3.38 Million; As Teva ...

Fri, 16 Jun 2017 19:52:30 GMT

SAGE Therapeutics Inc (SAGE) Shares Sold by BB Biotech AG

Sun, 11 Jun 2017 19:52:30 GMT

Investment summary

BB Biotech (BION) is a long-established investor in biotech innovation, offering access to a concentrated portfolio of c 30 companies covering a range of therapeutic areas. It seeks to provide long-term capital growth, but also offers a yield of c 5% as a result of a capital distribution policy adopted in 2012. Performance has been strong both over the long term and more recently, with the fund ranking first among peers (in Swiss franc terms) over one and five years, and also outperforming the benchmark NASDAQ Biotechnology Index over one, three, five and 10 years. Although biotech and healthcare stocks may continue to see some near-term share price volatility as the direction of US policy becomes clearer, BION’s managers point to lower-than-average biotech valuations as a source of support.

Last updated on 27/02/2017

Latest video

Bitesize Briefings - BB Biotech

Key management

Prof. Dr. Thomas Szucs, Chairman
Daniel Koller, Head of Management Team
Claude Mikkelsen, Director of IR
Dr. Silvia Schanz , Investor Relations

Company address

Seestrasse 16
Postfach
8700 Kusnacht / Zurich
Germany
+41 44 267 67 00
View website